164 related articles for article (PubMed ID: 28293193)
1. Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-Based Proteomic Analysis of Hugan Qingzhi and Its Protective Properties against Free Fatty Acid-Induced L02 Hepatocyte Injury.
Xia F; Yao X; Tang W; Xiao C; Yang M; Zhou B
Front Pharmacol; 2017; 8():99. PubMed ID: 28293193
[TBL] [Abstract][Full Text] [Related]
2. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.
Yao X; Xia F; Tang W; Xiao C; Yang M; Zhou B
J Ethnopharmacol; 2018 Feb; 212():208-215. PubMed ID: 29031784
[TBL] [Abstract][Full Text] [Related]
3. Hugan Qingzhi medication ameliorates free fatty acid-induced L02 hepatocyte endoplasmic reticulum stress by regulating the activation of PKC-δ.
Yang M; Chen Z; Xiang S; Xia F; Tang W; Yao X; Zhou B
BMC Complement Med Ther; 2020 Dec; 20(1):377. PubMed ID: 33308192
[TBL] [Abstract][Full Text] [Related]
4. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
Yin J; Luo Y; Deng H; Qin S; Tang W; Zeng L; Zhou B
J Ethnopharmacol; 2014 May; 154(1):229-39. PubMed ID: 24735863
[TBL] [Abstract][Full Text] [Related]
5. Hugan Qingzhi tablets attenuates endoplasmic reticulum stress in nonalcoholic fatty liver disease rats by regulating PERK and ATF6 pathways.
Yang M; Yao X; Xia F; Xiang S; Tang W; Zhou B
BMC Complement Med Ther; 2024 Jan; 24(1):36. PubMed ID: 38216941
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].
Yao XR; Xia F; Tang WJ; Zhou BJ
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan; 37(1):56-62. PubMed ID: 28109099
[TBL] [Abstract][Full Text] [Related]
7. Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease.
Tang W; Zeng L; Yin J; Yao Y; Feng L; Yao X; Sun X; Zhou B
Evid Based Complement Alternat Med; 2015; 2015():810369. PubMed ID: 26146507
[TBL] [Abstract][Full Text] [Related]
8. Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line.
Zhou D; Li BH; Wang J; Ding YN; Dong Y; Chen YW; Fan JG
PLoS One; 2016; 11(10):e0165224. PubMed ID: 27760195
[TBL] [Abstract][Full Text] [Related]
9. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
10. [The quality standard study on Hugan qingzhi tablets].
Zhou BJ; Yan YM; Huang SX; Yao YF; Zhang SY
Zhong Yao Cai; 2012 Apr; 35(4):644-7. PubMed ID: 23019914
[TBL] [Abstract][Full Text] [Related]
11. Heatstroke-induced hepatocyte exosomes promote liver injury by activating the NOD-like receptor signaling pathway in mice.
Li Y; Zhu X; Zhang M; Tong H; Su L
PeerJ; 2019; 7():e8216. PubMed ID: 31875151
[TBL] [Abstract][Full Text] [Related]
12. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Quality Markers in Hugan Qingzhi Formula by Integrating a Lipid-Lowering Bioassay with UHPLC-QQQ-MS/MS.
He F; Xiao CX; Wang CJ; Liang J; Cheng QQ; Zhang L; Zhou BJ; Zhou H
Evid Based Complement Alternat Med; 2020; 2020():1594350. PubMed ID: 35198030
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of geniposide in improving free fatty acid metabolism in rats with non-alcoholic fatty liver disease].
Liang HQ; Lin MT; Zhao X; Zhou HH; Wang HG; Li GH; Wang YJ; Zhang LM; Wang YY; Chen SD
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(3):470-475. PubMed ID: 28868866
[TBL] [Abstract][Full Text] [Related]
15. Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Spanos C; Maldonado EM; Fisher CP; Leenutaphong P; Oviedo-Orta E; Windridge D; Salguero FJ; Bermúdez-Fajardo A; Weeks ME; Evans C; Corfe BM; Rabbani N; Thornalley PJ; Miller MH; Wang H; Dillon JF; Quaglia A; Dhawan A; Fitzpatrick E; Moore JB
Proteome Sci; 2018; 16():4. PubMed ID: 29456458
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Qingzhi soft capsule on blood lipid level and pathology of the fatty liver in hyperlipidemic rats].
Tong L; Chen YY; Guo YL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):73-5. PubMed ID: 18227032
[TBL] [Abstract][Full Text] [Related]
17. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
[TBL] [Abstract][Full Text] [Related]
18. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
19. Differential proteomics analysis of liver failure in peripheral blood mononuclear cells using isobaric tags for relative and absolute quantitation.
Lin H; Tan QP; Sui WG; Chen WB; Peng WJ; Liu XC; Dai Y
Biomed Rep; 2017 Feb; 6(2):167-174. PubMed ID: 28357068
[TBL] [Abstract][Full Text] [Related]
20. Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells.
Wang JW; Wan XY; Zhu HT; Lu C; Yu WL; Yu CH; Shen Z; Li YM
PLoS One; 2014; 9(4):e96124. PubMed ID: 24788149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
